Product logins

Find logins to all Clarivate products below.


Biosurgical Agents | Market Insights | Europe | 2022

Procedure deferrals due to the COVID-19 pandemic severely impacted the European biosurgical agent market in 2020, and the elective nature of many postponed procedures will hinder the pace of recovery to some extent. However, as the situation improves, the European biosurgical agent market will grow modestly through the forecast period, driven by continuing growth in biosurgical procedures, rising awareness of the clinical benefits of these products on surgical outcomes, and the introduction of new products with enhanced features and expanded indications.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for laparoscopic devices in Europe across an 11-year period.

Related Medtech Insights Reports

Report
Interventional Cardiology Devices – Market Insights – Europe
The European interventional cardiology device market is highly competitive and poised for moderate growth over the forecast period, driven by increasing PCI volumes for complex CAD cases and the…
Report
Electrophysiology Mapping and Ablation Devices – Market Insights – Europe
The European EP mapping and ablation device market will grow moderately through 2035, driven by the rising prevalence of cardiac arrhythmias, improved access to treatment, advancements in ablation…
Report
Aortic Repair Devices – Market Insights – Europe
The European aortic stent graft market is the primary driver of growth in the aortic repair device market and will drive revenue expansion over the forecast period, supported by ongoing innovation…
Report
Cardiac Rhythm Management Devices – Market Insights – Europe
The European CRM device market will continue to grow modestly over the forecast period because of rising ICM procedure volumes, the introduction of dual-chamber leadless pacemakers, and increased…
Report
Gastrointestinal Endoscopy Devices – Market Insights – Europe
The European GI endoscopy device market will be driven primarily by the high incidence of gastric cancer and CRC in the region. Market growth will be supported by nationwide CRC and GI cancer…